Clinical Trial Update: Lipid Efficacy/Tolerability Study (0524A-020) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating lipid efficacy and tolerability (0524A-020) has completed. The study targeted primary hypercholesterolemia and mixed hyperlipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Hyperlipidemia

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolaemia, Mixed Hyperlipidaemia | Phase 3 | Status: COMPLETED